Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II booster study of AS03-adjuvanted H5N1 pandemic influenza candidate vaccine in previously primed adults
2007-000115-28Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of Adjupanrix in influenza (4 arms), sponsored by GSK. Primary endpoints: Humoral immune response 21 days after one booster administration and Persistence of humoral immune response about 14 months after priming. Started Jul 2007; status: completed.
02
Drugs
Adjupanrix
03
Conditions
influenza
Beyond the preview
Go deeper on 2007-000115-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000115-28.